Key result
Multifactorial post-COVID dyspnea stems primarily from pulmonary fibrosis, respiratory muscle weakness, CTEPH, and hyperventilation.
Why the study?
Shortness of breath is a common disabling symptom in post-COVID syndrome with varied causes, creating an urgent need to understand its pathogenetic and molecular mechanisms to guide therapeutic tactics.
Dyspnea in post-COVID syndrome is multifactorial, driven by pulmonary fibrosis, muscle weakness, thromboembolic complications, and hyperventilation, requiring tailored management strategies.
Supports multifactorial dyspnea assessment in post-COVID; leaves open standardized diagnostic and therapeutic algorithms for prospective studies.
Post-COVID syndrome is an actual problem at the present time. The shortness of breath is one of the most common complaints in this group of patients. Dyspnea is one of the most significant disabling symptoms that negatively affect the quality of life of patients. The causes and mechanisms for the development of dyspnea in the post-COVID period are varied. In particular, one of the main causes of dyspnea is fibrosis-like and fibrous changes in the. Fatigue and / or muscle weakness, in particular of the respiratory muscles, can also be the cause of dyspnea. Direct SARS-CoV-2 infection of skeletal muscles, drug-induced myopathy, prolonged immobilization of hospitalized patients may also result in muscle weakness. Increased risks of thrombosis and pulmonary embolism (PE) after COVID-19, creating conditions for the development of chronic thromboembolic pulmonary hypertension, represent another factors for the development of shortness of breath. In patients with no abnormalities in blood gases or any other parameters that assess the functioning of the cardiovascular and respiratory systems, hyperventilation syndrome can be the cause of dyspnea. Thus, studying pathogenetic and molecular mechanisms of dyspnea development is an urgent problem, due to the need for specialists to choose the right tactics and select effective drugs and non-drug therapy for managing patients with this complaint.
No takes yet. Share an insight, caveat, or question.
Pozdnyakova et al. (2023) conducted a review in Post-COVID syndrome. SARS-CoV-2 infection was evaluated. Dyspnea in post-COVID syndrome is multifactorial, primarily driven by pulmonary fibrosis, respiratory muscle weakness, chronic thromboembolic pulmonary hypertension, and hyperventilation syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: